



COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

**Investor Contact:**

Steven M. Harasym  
Vice President, Investor Relations  
Tel: +1 (301) 556-9850  
[investors@precigen.com](mailto:investors@precigen.com)

**Media Contacts:**

Donelle M. Gregory  
[press@precigen.com](mailto:press@precigen.com)

Glenn Silver  
Lazar-FINN Partners  
[glenn.silver@finnpartners.com](mailto:glenn.silver@finnpartners.com)

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/precigen-enters-into-agreement-to-divest-non-healthcare-subsiary-trans-ova-genetics-301580212.html>

SOURCE Precigen, Inc.